1. PPCB's PRP shows potential against pancreatic ductal adenocarcinoma. 2. Published findings in Scientific Reports highlight PRP's multifaceted effects. 3. Future Phase 1b study planned for Q3 2026 on advanced cancer patients. 4. PDAC is a leading cause of cancer-related deaths; PRP targets unmet needs. 5. CEO emphasizes transformative potential of PRP for PDAC patients.
FAQ
Why Bullish?
PPCB's development of PRP indicates significant potential in treating PDAC. Similar advancements have often led to increased stock valuation in biotech.
How important is it?
The article presents critical research supporting PPCB's product, influencing investor sentiment and potential market performance.
Why Long Term?
Long-term benefits expected from clinical trials and potential market approval. Past biotech successes often take years to materialize into market gains.
Propanc Biopharma (PPCB) Advances Cancer Research with New Study Findings
MELBOURNE, Australia, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB), a biopharmaceutical firm focused on creating innovative treatments for chronic diseases, including recurrent and metastatic cancers, has announced significant research outcomes in a recently published peer-reviewed article. The findings, co-authored with its collaborative research partners from the Universities of Jaén and Granada, appear in the journal Scientific Reports, and detail the effects of proenzymes on pancreatic ductal adenocarcinoma (PDAC) fibroblasts.
Research Insights and Implications
The research paper, entitled “Impact of pancreatic proenzymes on pancreatic ductal adenocarcinoma associated fibroblasts,” discusses the critical role of the tumor microenvironment (TME) in tumor initiation and progression. PDAC is known for its dense fibrotic stroma housing a substantial population of cancer-associated fibroblasts (CAFs). The interaction between these CAFs and tumor cells is vital for the advancement and metastasis of tumors, highlighting the need for innovative therapeutic strategies aimed at stromal cells to enhance patient survival.
- PRP (Pancreatic Proenzyme Therapy), derived from two bovine proteins—trypsinogen and chymotrypsinogen—has demonstrated effectiveness in cancer treatment.
- The study's results signify PRP as a candidate for disrupting the TME, showcasing its multifaceted effects on tumor dynamics.
Future Clinical Investigations
Future clinical trials are on the horizon to explore PRP's potential as an adjunct therapy for PDAC patients who are non-responsive to traditional treatment regimens. Despite advancements in cancer management, PDAC remains one of the most lethal and aggressive cancer forms, with projections indicating it could become the second leading cause of cancer-related deaths by 2030.
“Our findings demonstrate that PRP exerts multifaceted effects specifically over the CAFs population and tumor cells. All together, these results highlight PRP as a promising adjunct therapeutic candidate capable of disrupting key interactions within the PDAC TME,” said Dr. Belén Toledo, PhD, joint lead researcher from the University of Jaén.
James Nathanielsz, Propanc’s Chief Executive Officer, added, “After several years of research, we find ourselves publishing compelling scientific evidence that PRP has the potential to dramatically alter the treatment paradigm for patients diagnosed with this lethal disease. Our Phase 1b study is set to commence in Q3 2026, focusing on advanced cancer patients with solid tumors, including PDAC.”
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (Nasdaq: PPCB) is pioneering a novel approach to prevent cancer recurrence and metastasis by targeting and eliminating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, aims to address the fundamental drivers of cancer proliferation and spread.
For more information, visit www.propanc.com.
Forward-Looking Statements
Statements in this press release that are not historical facts are forward-looking statements, including expectations regarding market position and product development plans. These statements are based on current expectations and involve risks and uncertainties that may cause actual results to differ materially. Potential investors should review the Company’s filings with the SEC for a comprehensive understanding of the associated risks.